Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Defining secondary progressive multiple sclerosis

J. Lorscheider, K. Buzzard, V. Jokubaitis, T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand'Maison, P. Grammond, R. Hupperts, R. Alroughani, P. Sola, C. Boz, E. Pucci, J....

. 2016 ; 139 (Pt 9) : 2395-405. [pub] 20160707

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, pozorovací studie, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023858

A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.

Amiri Hospital Kuwait Kuwait

AORN San Giuseppe Moscati Avellino Italy

Cliniques Universitaires Saint Luc Brussels Belgium

Department of Basic Medical Sciences Neuroscience and Sense Organs University of Bari Bari Italy

Department of Biomedical and NeuroMotor Sciences Alma Mater Studiorum Università di Bologna Bologna Italy 9 IRCCS Istituto delle Scienze Neurologiche UOSI Riabilitazione Sclerosi Multipla Bologna Italy

Department of Medicine University of Melbourne Melbourne Australia

Department of Medicine University of Melbourne Melbourne Australia 2 Department of Neurology Royal Melbourne Hospital Melbourne Australia

Department of Medicine University of Melbourne Melbourne Australia 2 Department of Neurology Royal Melbourne Hospital Melbourne Australia 3 Department of Neurology Box Hill Hospital Monash University Melbourne Australia

Department of Medicine University of Sydney Sydney Australia

Department of Neurology and Center of Clinical Neuroscience Charles University Prague 1st Faculty of Medicine and General University Hospital Prague Prague Czech Republic

Department of Neurology John Hunter Hospital Newcastle Australia 18 School of Medicine and Public Health University of Newcastle Newcastle Australia

Flinders University and Flinders Medical Centre Adelaide Australia

Geelong Hospital Geelong Australia

Groene Hart Ziekenhuis Gouda The Netherlands

Hôpital Notre Dame Montreal Canada

Hospital de Galdakao Usansolo Galdakao Spain

Hospital Germans Trias i Pujol Badalona Spain

Hospital Italiano Buenos Aires Argentina

Hospital Universitario Donostia San Sebastian Spain

Hospital Universitario Virgen Macarena Seville Spain

Hôtel Dieu de Lévis Lévis Canada

Instituto de Neurosciencias INEBA Buenos Aires Argentina

Jewish General Hospital Montreal Canada

Karadeniz Technical University Trabzon Turkey

Kommunehospitalet Aarhus Denmark

Liverpool Hospital Liverpool Australia

Mondino National Neurological Institute of Pavia Italy

Nemocnice Jihlava Jihlava Czech Republic

Neuro Rive Sud Hôpital Charles LeMoyne Greenfield Park Canada

Neurology Unit ASUR Marche AV3 Macerata Italy

Nuovo Ospedale Civile S Agostino Estense Modena Italy

Orbis Medical Center Sittard The Netherlands

Ospedali Riuniti di Salerno Salerno Italy

South Eastern Trust Belfast Northern Ireland

The University of Queensland Brisbane Australia

University Hospital San Carlos Madrid Spain

University of Florence Florence Italy

University of Parma Parma Italy

Westmead Hospital Sydney Australia

000      
00000naa a2200000 a 4500
001      
bmc17023858
003      
CZ-PrNML
005      
20180518103122.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/brain/aww173 $2 doi
035    __
$a (PubMed)27401521
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lorscheider, Johannes $u 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
245    10
$a Defining secondary progressive multiple sclerosis / $c J. Lorscheider, K. Buzzard, V. Jokubaitis, T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand'Maison, P. Grammond, R. Hupperts, R. Alroughani, P. Sola, C. Boz, E. Pucci, J. Lechner-Scott, R. Bergamaschi, C. Oreja-Guevara, G. Iuliano, V. Van Pesch, F. Granella, C. Ramo-Tello, D. Spitaleri, T. Petersen, M. Slee, F. Verheul, R. Ampapa, MP. Amato, P. McCombe, S. Vucic, JL. Sánchez Menoyo, E. Cristiano, MH. Barnett, S. Hodgkinson, J. Olascoaga, ML. Saladino, O. Gray, C. Shaw, F. Moore, H. Butzkueven, T. Kalincik, . ,
520    9_
$a A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.
650    _2
$a dospělí $7 D000328
650    _2
$a kohortové studie $7 D015331
650    _2
$a konsensus $7 D032921
650    12
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chronicko-progresivní roztroušená skleróza $x diagnóza $x patofyziologie $7 D020528
650    12
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a validační studie $7 D023361
700    1_
$a Buzzard, Katherine $u 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia 3 Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.
700    1_
$a Jokubaitis, Vilija $u 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
700    1_
$a Spelman, Tim $u 1 Department of Medicine, University of Melbourne, Melbourne, Australia.
700    1_
$a Havrdova, Eva $u 4 Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Horakova, Dana $u 4 Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Trojano, Maria $u 5 Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.
700    1_
$a Izquierdo, Guillermo $u 6 Hospital Universitario Virgen Macarena, Seville, Spain.
700    1_
$a Girard, Marc $u 7 Hôpital Notre Dame, Montreal, Canada.
700    1_
$a Duquette, Pierre $u 7 Hôpital Notre Dame, Montreal, Canada.
700    1_
$a Prat, Alexandre $u 7 Hôpital Notre Dame, Montreal, Canada.
700    1_
$a Lugaresi, Alessandra $u 8 Department of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum - Università di Bologna, Bologna, Italy 9 IRCCS Istituto delle Scienze Neurologiche - "UOSI Riabilitazione Sclerosi Multipla" Bologna, Italy.
700    1_
$a Grand'Maison, François $u 10 Neuro Rive-Sud, Hôpital Charles LeMoyne, Greenfield Park, Canada.
700    1_
$a Grammond, Pierre $u 11 Hôtel-Dieu de Lévis, Lévis, Canada.
700    1_
$a Hupperts, Raymond $u 12 Orbis Medical Center, Sittard, The Netherlands.
700    1_
$a Alroughani, Raed $u 13 Amiri Hospital, Kuwait, Kuwait. $7 gn_A_00004804
700    1_
$a Sola, Patrizia $u 14 Nuovo Ospedale Civile S.Agostino/Estense, Modena, Italy.
700    1_
$a Boz, Cavit $u 15 Karadeniz Technical University, Trabzon, Turkey.
700    1_
$a Pucci, Eugenio $u 16 Neurology Unit, ASUR Marche, AV3, Macerata, Italy.
700    1_
$a Lechner-Scott, Jeanette $u 17 Department of Neurology, John Hunter Hospital, Newcastle, Australia 18 School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
700    1_
$a Bergamaschi, Roberto $u 19 Mondino National Neurological Institute of Pavia, Italy.
700    1_
$a Oreja-Guevara, Celia $u 20 University Hospital San Carlos, Madrid, Spain.
700    1_
$a Iuliano, Gerardo $u 21 Ospedali Riuniti di Salerno, Salerno, Italy.
700    1_
$a Van Pesch, Vincent $u 22 Cliniques Universitaires Saint-Luc, Brussels, Belgium.
700    1_
$a Granella, Franco $u 23 University of Parma, Parma, Italy.
700    1_
$a Ramo-Tello, Cristina $u 24 Hospital Germans Trias i Pujol, Badalona, Spain.
700    1_
$a Spitaleri, Daniele $u 25 AORN San Giuseppe Moscati, Avellino, Italy.
700    1_
$a Petersen, Thor $u 26 Kommunehospitalet, Aarhus, Denmark.
700    1_
$a Slee, Mark $u 27 Flinders University and Flinders Medical Centre, Adelaide, Australia.
700    1_
$a Verheul, Freek $u 28 Groene Hart Ziekenhuis, Gouda, The Netherlands.
700    1_
$a Ampapa, Radek $7 mzk2018987225 $u 29 Nemocnice Jihlava, Jihlava, Czech Republic.
700    1_
$a Amato, Maria Pia $u 30 University of Florence, Florence, Italy. $7 gn_A_00005308
700    1_
$a McCombe, Pamela $u 31 The University of Queensland, Brisbane, Australia.
700    1_
$a Vucic, Steve $u 32 Westmead Hospital, Sydney, Australia.
700    1_
$a Sánchez Menoyo, José Luis $u 33 Hospital de Galdakao-Usansolo, Galdakao, Spain.
700    1_
$a Cristiano, Edgardo $u 34 Hospital Italiano, Buenos Aires, Argentina.
700    1_
$a Barnett, Michael H $u 35 Department of Medicine, University of Sydney, Sydney, Australia.
700    1_
$a Hodgkinson, Suzanne $u 36 Liverpool Hospital, Liverpool, Australia.
700    1_
$a Olascoaga, Javier $u 37 Hospital Universitario Donostia, San Sebastian, Spain.
700    1_
$a Saladino, Maria Laura $u 38 Instituto de Neurosciencias INEBA, Buenos Aires, Argentina.
700    1_
$a Gray, Orla $u 39 South Eastern Trust, Belfast, Northern Ireland.
700    1_
$a Shaw, Cameron $u 40 Geelong Hospital, Geelong, Australia.
700    1_
$a Moore, Fraser $u 41 Jewish General Hospital, Montreal, Canada.
700    1_
$a Butzkueven, Helmut $u 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia 3 Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia butz@unimelb.edu.au.
700    1_
$a Kalincik, Tomas $u 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
700    1_
$a ,
773    0_
$w MED00009356 $t Brain a journal of neurology $x 1460-2156 $g Roč. 139, č. Pt 9 (2016), s. 2395-405
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27401521 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20180518103300 $b ABA008
999    __
$a ok $b bmc $g 1239539 $s 984771
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 139 $c Pt 9 $d 2395-405 $e 20160707 $i 1460-2156 $m Brain $n Brain $x MED00009356
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace